G3, Caprion to identify cardiovascular disease biomarkers and drug targets

As part of the deal, Caprion will identify blood-based protein markers for the GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) trial.

GLOBAL is a pan-omic study that combines genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics with coronary computed tomographic (CT) angiography, an advanced imaging technology for phenotyping, which allows precise disease classification of patients.

G3 chief executive officer and co-founder Szilard Voros said the company will analyze 22 trillion data points from the precise CT phenotyping and the pan-omic analyses with specifically-developed systems and biology-based bioinformatics, allowing us to understand the root causes of cardiovascular disease and ultimately enable us to identify novel diagnostic biomarkers and therapeutic targets.

"Caprion’s unbiased and targeted mass spectrometry-based proteomic platform will provide an in-depth assessment of plasma proteins to complement the other ‘omic’ approaches we are using in the GLOBAL study," Voros said.

Caprion will use its CellCarta technology to analyse and measure differential expression of proteins in plasma samples from the patients enrolled in GLOBAL.

CellCarta is an industrialized proteomic platform designed for large-scale studies that includes sample preparation, mass spectrometry, bioinformatics and biological expertise.

Caprion president and CEO Martin LeBlanc said, "Caprion is pleased to collaborate with G3, and we are proud to leverage our expertise in large-scale proteomics and personalized medicine to contribute to this landmark effort in such a clinically-relevant field."